Ads
related to: prostate cancer clinical trials 2023 registration- Find an Imaging Site
Locate the nearest imaging site
or contact customer service.
- Case Studies
Review real case studies
with real patients.
- Sign Up for Updates
Sign up to receive the latest data,
case studies, and resources.
- Contact Us
Contact our representatives
for product and reimbursement info.
- Find an Imaging Site
pfizerclinicaltrials.com has been visited by 10K+ users in the past month
Search results
Results from the WOW.Com Content Network
PROSTVAC is being developed in partnership with the National Cancer Institute under a formal Cooperative Research and Development Agreement and has been the subject of multiple ongoing and completed clinical studies, including the global Phase 3 PROSPECT study underway in patients with asymptomatic or minimally symptomatic metastatic prostate cancer (mCRPC). [2]
[1] [2] [3] It is specifically comparing three to four 100 μg/day estradiol patches (FemSeven or Progynova TS) against goserelin implants in approximately 2,200 men with prostate cancer. [1] [4] The study was started in March 2006 and is estimated for completion in August 2021, with additional reports expected in 2023 and 2024.
In 2006, scientists from Purdue University designed a targeting ligand that bound with high affinity and specificity to PSMA on prostate cancer cells and patented [13] [14] its ability to target attached radionuclides such as 177 Lu, 99m Tc, 68 Ga, etc. to prostate cancers. The patents were licensed to Endocyte in 2007.
Its shares hit a record high of $41.22, after declining 18.53% in 2023 and were on track to add more than $1.2 billion to its market capitalization, if gains hold.
The trial investigates new approaches for men with metastatic and locally advanced prostate cancer. [1] 117 hospitals in the UK and Switzerland are involved with over 10,000 men are expected to take part in the trial. [2] The men are randomly assigned to one of a number of "arms". The primary outcome by which the arms were judged is overall ...
AOH1996 is an experimental anticancer medication which acts as a small molecule inhibitor of proliferating cell nuclear antigen (PCNA) and is in Phase I clinical trials at City of Hope as of August 2023 for the treatment of solid tumors. [1] [2] [3] [4]
Ads
related to: prostate cancer clinical trials 2023 registrationpfizerclinicaltrials.com has been visited by 10K+ users in the past month